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ABSTRACT: To characterize the impact of metabolic disease on the peptidome of human and mouse
pancreatic islets, LC-MS was used to analyze extracts of human and mouse islets, purified mouse alpha,
beta, and delta cells, supernatants from mouse islet incubations, and plasma from patients with type 2
diabetes. Islets were obtained from healthy and type 2 diabetic human donors, and mice on chow or
high fat diet. All major islet hormones were detected in lysed islets as well as numerous peptides from
vesicular proteins including granins and processing enzymes. Glucose-dependent insulinotropic peptide
(GIP) was not detectable. High fat diet modestly increased islet content of proinsulin-derived peptides
in mice. Human diabetic islets contained increased content of proglucagon-derived peptides at the
expense of insulin, but no evident prohormone processing defects. Diabetic plasma, however, contained
increased ratios of proinsulin and des-31,32-proinsulin to insulin. Active GLP-1 was detectable in
human and mouse islets but 100−1000-fold less abundant than glucagon. LC-MS offers advantages
over antibody-based approaches for identifying exact peptide sequences, and revealed a shift toward
islet insulin production in high fat fed mice, and toward proglucagon production in type 2 diabetes,
with no evidence of systematic defective prohormone processing.
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■ INTRODUCTION
Pancreatic islets secrete multiple biologically active peptide
hormones, most notably insulin, glucagon, and somatostatin
(SST), but a number of recent studies have highlighted the
possibility that they might also secrete the incretin hormones,
glucagon-like peptide 1 (GLP-1)1−6 and glucose-dependent
insulinotropic peptide (GIP).7,8 Intraislet release of GLP-1 has
been postulated to modulate insulin secretion under conditions
such as metabolic stress, although it remains unclear whether it
is produced locally at levels sufficient to exert physiologically
significant effects on beta cells. The literature is complicated by
the use of antibody-based methods to detect and quantify
peptide hormones as these are prone to antibody cross-
reactivity, but improvements in mass spectrometry methods
now allow identification and quantification of exact peptide
sequences. This study aimed to identify the exact peptide
sequences produced and released from mouse and human
islets, and the impact of consuming a high fat diet or
development of type 2 diabetes.
Five islet cell populations have been described, including the
3 major cell types: beta cells producing insulin and islet
amyloid polypeptide (IAPP), alpha cells producing glucagon
and delta cells producing SST-14, together with rarer PP-cells
producing pancreatic polypeptide (PPY), and epsilon cells
producing ghrelin.9 Pancreatic islet development shares
common endodermal origins and transcription factor require-
ments with intestinal enteroendocrine cells, so it is not
surprising to find overlap of hormone expression between islets
and the gut. Indeed, the intestinal hormone peptide YY (PYY)
has been detected in alpha, delta, and gamma cells in mouse
but not humans.10,11 GIP has been detected as a shortened
version in human and mouse islets (GIP(1−30), compared
with (1−42) in the gut), although some antibodies against GIP
have been questioned due to their propensity to bind to
proglucagon derived peptides,12−14 and transcriptomic studies
failed to find expression of Gip in mouse11 or human islets.10
Proglucagon is processed by prohormone convertase (PC) 2
in islets to release glucagon, and by PC1/3 in the gut to
generate bioactive GLP-1(7−37/7−36amide). Longer forms
of GLP-1(1−37/1−36amide) have been identified in human
and rat pancreas15 and are not bioactive against the GLP-1
receptor (GLP1R) but cross-react with many antibodies
against GLP-1. Antagonizing GLP1R attenuates glucose-
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stimulated insulin secretion (GSIS) from human and mouse
islets even in the absence of an intestinal source of GLP-
1,4,6,16,17 suggesting a local islet source of a GLP1R agonist
peptide, but this need not be GLP-1, as glucagon itself acts on
the GLP-1 receptor, albeit with 50−100-fold lower potency
than active GLP-1.18,19 Several studies utilizing liquid
chromatography coupled to mass spectrometry (LC-MS)
have detected active GLP-1 in islets but have not commented
on its abundance relative to glucagon.1,20
In addition to clarifying controversies around intraislet GLP-
1 and GIP, unbiased LC-MS has potential for elucidating how
the islet peptidome responds to metabolic stress. Obesity is
well-known to increase insulin secretion, and in rodent models
causes beta cell hyperplasia.21 In type 2 diabetes (T2DM) and
diabetic mouse models, there have been reports of beta cell
dedifferentiation,22−24 increased alpha cell numbers, and islet
GLP-1 production.1,2
In this study, we used LC-MS to probe the peptidome of
human and mouse islets in health and under conditions of
obesity and T2DM, and to analyze intraislet production of
incretin peptides. Using similar LC-MS peptidomic methods,
we have previously identified and quantified endocrine
peptides in a variety of tissues, plasma, and cell super-
natants.25−27
■ METHODS
Unless otherwise stated, all chemicals were obtained from
Sigma-Aldrich (Poole, UK). GLP-1(7−36 amide) and
glucagon standards were from Bachem (Bubendorf, Switzer-
land). Internal standards for GLP-1(7−36 amide) and
glucagon were from Cambridge Research Biochemicals
(Billingham, UK).28
Mice
All work was conducted in keeping with the Animals (Scientific
Procedures) Act 1986 Amendment Regulations of 2012 and
approved by the University of Cambridge Animal Welfare and
Ethical Review Board under project licenses 70/7824 and
PE50F6065. Mice (either gender, if not stated otherwise) were
on a C57BL/6 background, bred in-house under SPF
conditions and between 10 and 29 weeks old. For the diet-
induced obese (DIO) study, 9−15 week old male mice were
assigned to 1 of 2 groups; one fed high fat diet (HFD) (60%
fat, Research Diets) for 13 weeks and the other standard chow.
Fasting blood glucose levels were taken after 6 h fast. Sixty
islets from each mouse were isolated and lysed as below.
Islet Isolation
Mice were sacrificed by cervical dislocation and the pancreas
injected with ice-cold Collagenase V (0.75 mg/mL) in HBSS.
After digesting the pancreas at 37 °C for 12 min, islets were
washed and hand-picked into HBSS with 0.1% BSA (w/v).
Islet Lysate Peptidomics
Islets were washed in HBSS before lysing in a Protein LoBind
Eppendorf with 200 μL 6 mol/L guanidine hydrochloride
(GuHCl). Three freeze thaw cycles were carried out to aid cell
lysis. Proteins were precipitated by adding 800 μL of 80%
ACN (v/v) and centrifuging at 4 °C for 5 min at 12 000g. The
aqueous lower phase containing the peptides was collected,
dried in a centrifugal evaporator overnight and stored at −70
°C.
Isolation of Islet Cell Populations
Beta, alpha, and delta cell populations were purified using an
Influx Cell Sorter (BD Biosciences, Franklin Lakes, NJ) at the
Cambridge Institute for Metabolic Research flow cytometry
group. Beta and alpha cells were purified from islets of Glu-
GFP mice and delta cells from Sst-Cre/EYFP mice, as
described previously.11 Cells were sorted into 200 μL 6 mol/
L GuHCl, then treated as described for islet lysates.
Islet Secretion Assays
Fresh islets were incubated at 37 °C in Kreb’s Ringer Buffer
(KRB (mmol/L); 129 NaCl, 5 NaHCO3, 4.8 KCl, 1.2
KH2PO4, 1.2 MgSO4, 10 HEPES, 2.5 CaCl2 with 0.05% BSA
(w/v) for 1 h. Islets were transferred to Protein LoBind
Eppendorf tubes with 300 μL of prewarmed KRB containing
stimuli detailed in figure legends. Tubes were incubated at 37
°C for 45 min, then 270 μL of supernatant was removed and
snap frozen. Nine supernatants were pooled for LC-MS
analysis.
Human Islet Study
Ethical approval was obtained from University of Cambridge
Human B i o l o g y R e s e a r c h E t h i c s Comm i t t e e
(#HBREC.2019.38). Human islets for research were provided
by the Alberta Diabetes Institute IsletCore at the University of
Alberta in Edmonton (www.isletcore.ca) with the assistance of
the Human Organ Procurement and Exchange (HOPE)
program, Trillium Gift of Life Network (TGLN) and other
Canadian organ procurement organizations. Islet isolation was
approved by the Human Research Ethics Board at the
University of Alberta (Pro00013094). All donors’ families
gave informed consent for the use of pancreatic tissue in
research. Donor characteristics (mean ± st. dev.) are Controls
(6 male, 3 female), age 50 ± 5 years, BMI 30 ± 3 kg/m2;
T2DM (3 male, 4 female), age 52 ± 7 years, BMI 28 ± 4 kg/
m2, HbA1c 7.3 ± 1.2%, (1 diet-controlled, 4 on metformin, 1
on other oral antihyperglycemic agent, 1 on insulin).
Measurements of islet insulin content and Islet Particle Index
(a measure of islet size), generated by the Alberta Islet Core at
the time of tissue collection, were not significantly different
between the T2DM and control groups. Anonymized, snap
frozen human islets (2000 islet equivalents (IEQ) per donor,
i.e., the standardized equivalent of 2000 islets of diameter 150
μm) were thawed, washed 3× with HBSS, spun at 200g for 5
min at 4 °C, and supernatants discarded. Islets were lysed in
250 μL of 6 mol/L GuHCl with 3 freeze thaw cycles, and
proteins precipitated as above.
Preparation of Standard Curves
Calibration curves for glucagon and GLP-1(7−36amide) were
prepared in matrix comprising mouse pancreatic acinar tissue
from which visible islets had been removed, treated with
GuHCl and ACN, as above. Internal standards for glucagon
and GLP-1(7−36amide) were spiked into calibration stand-
ards and islet lysates.
Solid Phase Extraction, Reduction, and Alkylation
Solid phase extraction (SPE), reduction and alkylation, were
performed as described previously.29 Cellular lysates were
reconstituted in 0.1% FA (v/v) and supernatants acidified with
formic acid to a final percentage of 0.1% (v/v). Samples were
extracted on an Oasis PRiME HLB μElution plate (Waters,
Milford, MA). Only cellular lysates were reduced and alkylated.
Supernatants were run immediately after SPE.
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Nano LC-MS
For detailed methods on columns, source settings, gradient
details, and database searching see ref 29. Briefly, samples were
analyzed on a Thermo Fisher UltiMate 3000 Nano LC system
coupled to a Q Exactive Plus Orbitrap mass spectrometer
(ThermoScientific, San Jose, USA) using electrospray ioniza-
tion in positive mode. Method run time was 130 min with a
full MS scan on ions between 400 and 1600 m/z prior to a
MS/MS scan 10 top ions per scan. Product ion scans were
used to monitor for specific ions given in Supplementary Table
S1. Data files were searched against the mouse SwissProt
database (downloaded 26/10/2017) using PEAKS v8.5
software (Waterloo, Ontario, Canada). To quantify data
acquired by product ion scans, Xcalibur v4.3.73.11 (Thermo
Fisher Scientific) was used to integrate area under the curve on
the chromatogram.
Human Plasma
Stored human plasma from the placebo arm of a previous
study30 in which healthy volunteers and patients with type 2
diabetes received a 75 g oral glucose tolerance test, was
analyzed by LC-MS to measure insulin, proinsulin and des 31−
32 proinsulin. Samples were extracted using well established
methods31 and analyzed on a microflow LC system, coupled to
a HSS T3 ionKey (Waters) on the TQ-XS spectrometer. Ten
μL of sample was injected onto a trap column at 15 μL/min for
a 3 min load, with mobile phases set to 90%A (0.1% formic
acid (aq)) and 10% B (0.1% formic acid (acetonitrile)). The
ionKey column was set at 45 °C and the analytes were
separated over a 13 min gradient from 10% to 55% B, at a flow
rate of 3 μL/min. The column was flushed for 3 min at 85% B
before returning to initial conditions, resulting in an overall run
time of 20 min. Targeted SRM transitions were set up based
on parent and precursor ion fragments for each peptide
(Supplementary Table S2). Peptide peak areas were quantified
Figure 1. Overview of peptides produced from prohormones in mouse and human islets. Quantification of peptides derived from classical islet
prohormones by DDA in mouse islets (a), and human islets (b). Peptides derived from prourocortin-3 and proenkephalin-B in mouse islets (c) and
peptides derived from proVGF in human islets (d). If peptides do not have an assigned name in the literature then peptides are named for their
gene of origin as well as their position on that gene; e.g., Pdyn_177−199 originates from Pdyn and spans amino acids 177−199. Mouse data from 7
mice. Human data from 9 individuals. N.B. The A chains of insulin-1 an insulin-2 are identical and so only 1 peptide is displayed for the insulin A
chain.
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using MassLynx v4.2 (Waters) and normalized as peak area
ratio against an internal standard, bovine insulin.
Data Analysis
Data visualization and statistical analysis were carried out using
RStudio (v1.3) and R (v4.0.2). When peptidomic differences
between one or more groups needed to be assessed, the
outputs of PEAKS database searches were obtained and
analyzed in R. To control for multiple comparisons, P values
were adjusted using a permutation-based method using
Perseus (Max Planck Institute of Biochemistry, v1.6.14.0).
■ RESULTS
Peptidomics of Human and Mouse Islets
The major islet hormonesinsulin, glucagon, SST, PPY, and
IAPPwere detected by LC-MS/MS in extracts of lysed
human and mouse islets (Figure 1a,b). Using data dependent
acquisition (DDA), we also detected a range of other peptides,
including proinsulin, C-peptide, and partially processed
insulins, as well as GRPP (the N-terminus of proglucagon)
and inactive forms of GLP-1 (1−36amide and 1−37). Active
GLP-1 was detectable only in the human samples with this
method (Figure 1b). An N-terminal fragment of ghrelin
(GHRL_24−37) was detected in human islets, but full length
and acylated versions of ghrelin were not detectable in either
species. In mouse islets we detected PYY and fragments of
prourocortin-3 and proenkephalin-B (alpha-neoendorphin and
rimorphin)32,33 (Figure 1c), and in human islets we found
peptides from neurosecretory protein VGF (Figure 1d). We
also detected a number of peptides derived from granin
proteins and vesicular processing enzymes (Supplementary
Figure S1).
Peptidomics of Purified Alpha, Beta, and Delta Cells
We determined the cellular origin of the different peptides by
analyzing FACS-purified mouse alpha, beta and delta cells.
Across all islet cell samples, 999 peptides were matched by
PEAKS database searching, of which 559 were detectable in at
least 2 samples. Peptides from proinsulin, proglucagon and
proSST separated across the beta, alpha and delta cells
respectively, as expected (Figure 2a and Supplementary Table
S3). Pancreatic polypeptide (PPY) was detected in alpha and
delta cells, although our method of cell separation may have
excluded collection of a cell type specifically expressing PPY.
PYY was mostly found in delta cells. Peptides from urocortin 3
and proenkephalin-B were found at highest levels in beta cells,
together with IAPP (Supplementary Table S3). Most peptides
were predominantly identified in a single cell population
(Figure 2b and Supplementary Table S3).
Intraislet GLP-1 and GIP
Although active forms of GLP-1(7−36amide and 7−37) were
readily detectable in human islets, their peak areas were
substantially smaller than those of either glucagon or N-
terminally extended inactive GLP-1(1−36 amide and 1−37)
(Figure 1b and 3c). From standard curves for glucagon and
GLP-1(7−36amide), we estimated that human islets contained
1.2 ± 0.4 pg/IEQ (mean ± SEM, n = 9) of GLP-1(7−
36amide), whereas glucagon concentrations were above the
highest calibration standard, equivalent to >150 pg/IEQ, with
an estimated value of ∼370 pg/IEQ (Supplementary Figure
S2). From both the calibrated results and the peak areas shown
in Figure 1 and 3c, the glucagon:GLP-1 ratio in human islets
was estimated to be >100:1, and likely closer to 300:1.
In mouse islet lysates, GLP-1(7−36amide and 7−37) could
be detected when we used product ion scans to monitor for
their fragments, even though they had not been detectable in
DDA mode (Supplementary Figure S3). Both b and y ions
Figure 2. Peptidomics of FACS purified mouse alpha beta and delta
cells. (a) Abundance of major islet hormones in the three FACS
purified islet cell populations. (b) Heatmap of all peptides matched
through Peaks database searching in the 3 purified cell populations. In
all plots, the peak area of each peptide was normalized to the number
of cells in that sample to account for differences in cell numbers. For
alpha and beta FACS purified cells, 3 separate samples were obtained
from 3 individual mice, whereas delta cells from 3 pairs of mice were
pooled to obtain 3 samples.
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matching GLP-1 were identified from a peak that coeluted with
a standard for GLP-1(7−36 amide), providing compelling
evidence for the intraislet production of GLP-1(7−36 amide)
in mouse as well as humans. Using the product ion scanning
approach, we again estimated the relative abundance of
different proglucagon-derived peptides (Figure 3a). Using
standard curves, glucagon was quantifiable at 3900 ± 400 pg/
islet (mean ± SEM, n = 7) whereas GLP-1(7−36 amide) and
GLP-1(7−37) were below the lower limit of quantification,
and likely therefore <0.8 pg/islet. Both the calibrated data and
peak areas suggest a glucagon:GLP-1 ratio of >1000:1 in
mouse islets (Figure 3b and Supplementary Figure S2).
Product ion monitoring was also used to search for proGIP
derived peptides in mouse islets as none were detected using
DDA. We were unable to detect GIP(1−42) (the intestinal
form), C-terminally truncated GIP(1−30) (previously de-
scribed in islets12), or a peptide from the N-terminus of
proGIP (Gip_22−43) that we can identify robustly in
homogenized mouse duodenal tissue (Supplementary Figure
S4−S6). GIP was also not detectable in human islets by DDA
analysis.
Figure 3. Proglucagon derived peptides. (a,b) Peptides in mouse islets quantified by monitoring for specific product ions after fragmenting
precursor ions specific to each peptide. (a) Quantification of proglucagon derived peptides in islet lysates from 7 mice. Each sample contained 60
islets. (b) Ratios of proglucagon derived peptides to glucagon in mouse islets. (c) Ratios of proglucagon derived peptides to glucagon, monitored
by DDA, in human islets.
Figure 4. Peptidomic comparison of islets from DIO mice and to lean controls. Body weights (a) and fasting blood glucose levels (b) of DIO mice
vs lean controls. (c−e) Volcano plots displaying log2 fold change vs −log10 of the adjusted p value for each peptide. Horizontal dotted line
indicates significance threshold of p = 0.05. A positive log2 fold change indicates an increase in DIO mice. 718 t tests were performed to analyze for
significant differences in peptides matched between the groups with a permeation-based method used to adjust for multiple comparisons. In (d,e),
peptides from different prohormones are colored in each plot: IAPP and INS derived peptides in (d). GLUC, SMS, PPY, and PYY derived peptides
in (e). (f) Peak area of processed insulin-1 and -2 chains in addition to proinsulin-1 and -2. Statistical comparison made using unpaired t test
without adjustments for multiple comparisons. *p < 0.05. n = 7 for control group and n = 8 for DIO group.
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Peptidomics of Lean versus Diet-Induced Obese (DIO)
Mouse Islets
To assess the effect of obesity on the islet peptidome, mice
were fed a high-fat diet for 13 weeks, at the end of which they
displayed higher body masses and fasting blood glucose than
chow-fed controls (Figure 4a,b). Size-matched islets from both
groups were compared by LC-MS/MS, with the results
depicted in volcano plots (Figure 4c−e). Fully processed
insulin-1, insulin-2, glucagon, SST, and PPY were not
significantly different between the groups. However, a number
of other fragments from proinsulin and proIAPP were
significantly increased in the islets from DIO mice (Figure
4d), as well as 2 peptides from proPYY (Figure 4e). Peptides
from granins and processing enzymes were largely unchanged
(Supplementary Figure S7a−c and Supplementary Table S4).
Manual quantification of proinsulins-1 and -2, which are too
long to be matched automatically by the PEAKS software,
revealed a significant increase in proinsulin-1 and -2 in the
DIO islets (Figure 4f).
Peptidomics of Type 2 Diabetic Islets and Plasma
To investigate the effects of type 2 diabetes on the islet
peptidome, we compared nondiabetic and diabetic islets
(Figure 5a−c, Supplementary Figure S7d,e and Supplementary
Table S5). No individual peptides were significantly altered in
diabetes when p-values were adjusted for multiple compar-
isons. However, multiple peptides from proinsulin and IAPP
clustered on the “reduced in T2DM” side of the volcano plot,
whereas peptides from proglucagon clustered on the “increased
in T2DM” side (Figure 5b). Somatostatin-derived peptides
exhibited no clear divide, and peptides from PPY were mostly
increased in diabetes (Figure 5c).
Manual quantification confirmed significant reductions in
insulin A and B chains but not proinsulin in the T2DM group
(Figure 5d) and increases in glucagon and GLP-1(7−36amide)
Figure 5. Peptidomic comparison of human islets from type 2 diabetic individuals compared to nondiabetic controls. (a) Volcano plot displaying
log2 fold change vs −log10 of the adjusted p value for each peptide. Horizontal dotted lines indicates p = 0.15. A positive log2 fold change indicates
an increase in T2DM. (b,c) Volcano plots displaying in different colors individual peptides derived from proIAPP, proinsulin, and proglucagon (b),
and from prosomatostatin, proPPY, and proVGF (c). (d,e) Manually quantified peak areas of processed insulin chains and proinsulin (d), and
products of proglucagon processing (e). (f) Ratio of peak area of glucagon:GLP-1(7−36amide) in all samples. Statistical comparison made using
unpaired t test without adjustments for multiple comparisons. *p < 0.05. For a−f, n = 9 for the control group and n = 7 for T2DM group. Donors
were excluded from the analysis if the samples failed to load properly onto the SPE sorbent. (g,h) Plasma des-31,32 proinsulin (g) and proinsulin
(h) plotted against insulin for control (gray) and T2DM (black) subjects in the fasting state (circles), and 30 min (squares) or 90 min (triangles)
after a 75 g oral glucose tolerance test. Values represent peak area ratios. (i,j) Ratios of data shown in (g,h). *p < 0.05 between controls and T2DM
by 2-way ANOVA.
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(Figure 5e). Using a calibration line, GLP-1(7−36amide)
increased from 1.2 ± 0.4 pg/IEQ (mean ± SEM; n = 9
nondiabetic donors) to 3.6 ± 0.9 pg/IEQ (n = 7 diabetic
donors, p = 0.025). However, although glucagon measure-
ments were above the top calibration standard, the peak area
ratio for glucagon increased in parallel, and the ratio of peak
areas for glucagon:GLP-1 was not significantly different
between the groups (Figure 5f), suggesting an overall increase
in proglucagon biosynthesis (which could reflect either a
change in alpha cell number, or proglucagon biosynthesis per
cell) rather than a change in processing.
Proinsulin products were also measured by LC-MS/MS in
the plasma of control and diabetic volunteers. Both before and
after an oral glucose challenge, we observed elevated
circulating levels of proinsulin and des-31,32 proinsulin in
the diabetic group, which were proportionally increased
following glucose ingestion, suggesting that incompletely
processed proinsulin products exhibit glucose-sensitive secre-
tion and are coreleased with insulin following glucose challenge
(Figure 5g,h).
Secretory Patterns from Mouse Islets
Mouse islets were incubated with low (1 mmol/L), medium (6
mmol/L) or high (16.7 mmol/L) glucose, or low glucose +
adrenaline (10 μmol/L), to trigger differential secretion from
alpha, beta and delta cells. Proglucagon-derived peptides and
PPY showed higher secretion in the low glucose + adrenaline
condition, whereas proinsulin-derived peptides, IAPP and SST
exhibited highest secretion in high glucose (Figure 6). Active
GLP-1 and peptides from proenkephalin-B and urocortin 3
were not detectable in islet supernatants.
■ DISCUSSION
This study presents a detailed analysis of the human and
mouse islet peptidome with a focus on peptides derived from
secretory granules, together with corresponding measurements
in murine obesity and human T2DM. Mostly we applied a
semiquantitative approach that enabled comparisons between
the same peptide in different specimens, but did not generate
exact concentrations. For glucagon and GLP-1, the additional
use of calibration standards allowed assessments of actual
peptide contents. We are not able to draw conclusions about
the presence or absence of peptides that were undetectable
using this methodology and for which we did not include
individual peptide standards, because different peptides are not
uniform in their behavior during the extraction steps and LC-
MS analysis.
In addition to peptides from proinsulin, proglucagon, and
prosomatostatin, we identified some rarer peptides originating
from VGF in human islets, and from PYY, prourocortin-3 and
proenkephalin-B in mouse islets. Proenkephalin-B is primarily
expressed in the brain34 where it is processed to multiple
Figure 6. Peptidomics of secretions from mouse islets. (a−c) Peak areas of peptides in supernatants of islets cultured in low, medium, or high
glucose, or low glucose + adrenaline. IAPP and insulin-derived peptides (a), proglucagon-derived peptides (b), PPY and SST-14 (c). Individual
data points are displayed in each plot along with the mean. Conditions were as follows; LG = 1 mmol/L glucose, LG + Adr = 1 mmol/L glucose +
5 μmol/L adrenaline, MG = 6 mmol/L glucose, HG = 16.7 mmol/L glucose. n = 5 with each data point representing pooled supernatants from 9
tubes each containing 15 islets. Islets obtained from 15 mice. (d) Heatmap of mouse islet secretion peptidomics. Data presented as Z-score of each
row. Gray squares within the heatmap indicate where peptides were not detectable. PyySP_68-100 is a peptide from a splice variant of Pyy which
has 2 amino acids inserted into the C-terminus of the propeptide. It was quantified in lieu of Pyy_68-98 which was undetectable.
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opioid receptor agonists such as α-neoendorphin and
rimorphin,32,33 but has not been described previously in islets.
As opioid receptors were not detected in human or mouse
islets by RNA sequencing,10,11 it seems unlikely that
proenkephalin-products are a key player in intraislet cross
talk. Urocortin-3 was described previously in pancreatic beta
cells35 and confirmed here by LC-MS.
Mirroring reports that Gip mRNA is not detectable in
islets10,11 and absence of islet Cre-reporter activity in GIP-Cre
mice,36 we could not detect proGIP derived peptides in mouse
or human islets despite using targeted product ion scans to
monitor for 3 individual proGIP peptides that are readily
detectable in duodenum.25 We conclude it is highly unlikely
that human or mouse islets produce GIP.
Estimates for islet glucagon content measured by LC-MS
were similar to those measured previously by ELISA.37−39
Active GLP-1(7−36 amide and 7−37) was detectable by LC-
MS in mouse and human islets, but at 400 to 1000-fold lower
levels than glucagon. Very low levels and secretion of active
GLP-1 relative to glucagon were previously reported in mouse
islets,4,16 but other studies using antibody-based approaches
that are less able to discriminate GLP-1(7−37/36amide) from
GLP-1(1−37/36amide) have calculated islet GLP-1 produc-
tion to be much higher.2,4,40 Our LC-MS approach readily
detected N-terminally extended GLP-1(1−37/1−36amide) in
human and mouse islets, with peak areas ∼10-fold higher than
corresponding GLP-1(7−37/36amide) forms. Despite the
relatively low production of active GLP-1 by pancreatic alpha
cells, a number of studies have concluded that intraislet
production of proglucagon-derived peptides influences insulin
secretion through beta cell GLP1R.4,6,16,40 The difference in
potency between GLP-1(7−36amide) and glucagon on
GLP1R has been estimated at 50 to 400-fold,16,19,41,42 so our
finding of 300−1000 times more glucagon than active GLP-1
in islets would favor glucagon as the local dominant agonist on
beta cell GLP1R. All detectable proglucagon fragments were
released in parallel in secretion experiments, exhibiting lower
release at high glucose, suggesting that signaling from alpha to
beta cells via GLP1R might diminish in importance following a
simple rise in plasma glucose concentration. However, GLP1R-
dependent cross-talk between alpha and beta cells might be
higher in situations when alpha cells are simultaneously
activated, such as in the postprandial state when they are
directly stimulated by amino acids and/or gut-derived GIP, as
also suggested by a recent study.43
In islets from DIO mice we observed an increase in the
abundance of proIAPP, proinsulin-1 and -2 derived peptides,
consistent with reports of β-cell hyperplasia in similar
models.44−46 However, as we deliberately matched islet sizes
between the control and DIO group, our analysis would have
excluded larger islets with beta cell hyperplasia, reducing our
ability to quantify differences in islet insulin content. No other
significant peptidomic changes were seen in DIO mouse islets,
supporting an RNA-sequencing based approach which
similarly did not find major transcriptomic differences in
alpha cells between DIO and lean mice.47
To our surprise, we detected only limited peptidomic
changes in islets from diabetic human donors. However, as
islets had a mean culture time of 43 h in 5.5 mmol/L glucose
and cold ischemia time of 14 h prior to freezing, this may have
been sufficient to reverse effects of hyperglycemic stress
encountered in vivo. As we only analyzed samples from 9
control and 7 diabetic donors, across a spectrum of diabetes
severity, this study is not powered to correlate peptidomic
changes with patient phenotypes, or identify changes in specific
subgroups. Overall, diabetic islets exhibited a global reduction
in peptides from proinsulin and IAPP and a corresponding
increase in peptides from proglucagon, with no evident change
in SST. This mirrors results from a previous study measuring
insulin, glucagon, and SST contents in pancreatic tissue from
T2DM and nondiabetic donors, which reported lower insulin
content per gram of tissue in the diabetic group and not
significantly altered glucagon or SST, although reductions in
the total pancreatic contents of insulin and SST content were
evident when the smaller overall weight of T2DM pancreas
was taken into account.48 Contrary to our expectations, based
on previous reports that T2DM is associated with increased
circulating proinsulin levels49,50 and increased islet GLP-1
production,1 we found no evidence of substantially altered
proinsulin or proglucagon processing in T2DM islets. Some
studies have suggested that beta cells dedifferentiate in
diabetes, taking on partial alpha cell phenotypes and expressing
GCG together with PC1/3.22,51 In theory, this could generate
cells capable of producing GLP-1(7−36amide) from proglu-
cagon, potentially explaining previous reports of increased islet
GLP-1 generation in diabetes. Although manual quantification
of our LC-MS data revealed a significant increase in active
GLP-1 in diabetic islets, this was mirrored by an increase in
glucagon with no change in the glucagon:GLP-1 ratio, arguing
against a major alteration in proglucagon processing.
Despite detecting no shift in insulin processing in diabetic
islets, in plasma from a separate group of diabetic volunteers,
we noticed an increase in the ratio of proinsulin and des-31,32
proinsulin to mature insulin, compared with healthy controls,
supporting a number of previous studies employing immuno-
assays.49,50 Proinsulin and des-31,32 proinsulin increased
proportionally with insulin following glucose ingestion,
suggesting that both peptides are released in parallel in vivo.
The finding of increased plasma proinsulin and des-31,32
proinsulin in plasma from the diabetic group, without
corresponding increases in partially processed insulin frag-
ments in the islets, is compatible with the idea that islets in
type 2 diabetes release more immature vesicles containing
incompletely processed proinsulin.
In conclusion, this analysis has identified the spectrum of
peptides produced by human and mouse islets in health and
metabolic disease, including post-translational modifications
and exact peptide sequences. While we could detect active
GLP-1 in both human and mouse islets, levels were 100−1000
fold lower than glucagon, suggesting that the activity of
glucagon on beta cell GLP1R would overcome any effect of
local GLP-1 production. Locally released GLP1R agonist
peptides could contribute to postprandial insulin release,
particularly when alpha cells are stimulated by elevated levels
of intestinal GIP and amino acids.
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